Biomerica Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>BI</div>
BMRA -- USA Stock  

USD 5.61  0.05  0.88%

Biomerica is scheduled to announce its earnings tomorrow. The upcoming quarterly report is expected on the 21st of October 2020. As many baby boomers are still indifferent towards healthcare space, it makes sense to break down Biomerica as a potential position. Should we be more optimistic in anticipation of a recovery?
Published over a week ago
View all stories for Biomerica | View All Stories
Should you continue to hold Biomerica (NASDAQ:BMRA) based on the current analyst consensus?
Biomerica is UNDERVALUED at 8.65 per share with modest projections ahead. We provide trade advice to complement the prevailing expert consensus on Biomerica. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Biomerica? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Biomerica this year

Annual and quarterly reports issued by Biomerica are formal financial statements that are published yearly and quarterly and sent to Biomerica stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Biomerica often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Biomerica utilizes its cash?

To perform a cash flow analysis of Biomerica, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Biomerica is receiving and how much cash it distributes out in a given period. The Biomerica cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Biomerica Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (4.3 Million)

Biomerica exotic insider transaction detected

Legal trades by Biomerica insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Biomerica insider trading alert for general transaction of non qualified stock option by Sloan Steven, Chief Financial Officer, on 3rd of September 2020. This event was filed by Biomerica Inc with SEC on 2020-09-03. Initial filing of beneficial ownership - SEC Form 3 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Biomerica a risky opportunity?

Let's check the volatility. Biomerica is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Biomerica (NASDAQ:BMRA) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. taking in a share of a Biomerica stock makes you a part-owner of that company.

Some Biomerica technical indicators suggest turnaround

The expected short fall is down to -4.67 as of today. Biomerica is displaying above-average volatility over the selected time horizon. Investors should scrutinize Biomerica independently to ensure intended market timing strategies are aligned with expectations about Biomerica volatility.

Our Bottom Line On Biomerica

When is the right time to buy or sell Biomerica? Buying stocks such as Biomerica isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. The inconsistency in the assessment between current Biomerica valuation and our trade advice on Biomerica is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Biomerica.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Biomerica. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com